Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics

被引:6
|
作者
Ngo, Lien [1 ]
Yoo, Hee-Doo [1 ]
Tran, Phuong [1 ]
Cho, Hea-Young [2 ]
Lee, Yong-Bok [1 ]
机构
[1] Chonnam Natl Univ, Inst Bioequivalence & Bridging Study, Coll Pharm, 77 Yongbong Ro, Gwangju 61186, South Korea
[2] CHA Univ, Coll Pharm, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggido, South Korea
基金
新加坡国家研究基金会;
关键词
Rebamipide; Population; Pharmacokinetics; Genetic polymorphism; MDR1; MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN EXPRESSION; ORAL BIOAVAILABILITY; HELICOBACTER-PYLORI; ANTIULCER AGENT; SOLID DISPERSION; MALE-VOLUNTEERS; MDR1; GENE; POLYMORPHISMS; DRUG;
D O I
10.1007/s10928-017-9519-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, the population pharmacokinetic (PK) analysis of rebamipide (Reba) in healthy male Korean subjects was analyzed using the nonlinear mixed effects modeling method. The possible effects of physiological covariates and the multidrug resistance (MDR1) gene 3435C > T polymorphism on PK parameters were also investigated. Data were collected from a bioequivalence study, in which 26 subjects who participated in the study were administered a single oral dose of 100 mg Reba; only data from the reference formulation were used. Reba showed a relatively large inter-individual variability (from 2.6- to 3.3-fold) in the PK parameters with double peaks or the concentration plateau after the peak concentration in its serum concentration-time profiles. The population PKs of Reba was best described by a one-compartment model with three fraction absorption processes followed a single Weibull-type function and two first-order kinetics, and lag times. The study suggests that the efflux transporter MDR1 3435C > T allele affects the substantial inter-individual variability in the absorption of Reba according to genetic polymorphism. A significant difference was found in the absorption rate ka (1) among the MDR1 3435C > T genotype groups (P < 0.05) (CT group, 79.8% increase; and TT group, 115% increase). The use of combined MDR1 3435C > T and body mass index as covariates for ka (1) exerted a more significant effect (P < 0.05). In addition, body surface area significantly affected the apparent total clearance (P < 0.05).
引用
下载
收藏
页码:291 / 303
页数:13
相关论文
共 50 条
  • [21] Population pharmacokinetics of aripiprazole in healthy Korean subjects
    Jeon, Ji-Young
    Chae, Soo-Wan
    Kim, Min-Gul
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (04) : 293 - 304
  • [22] Population Pharmacokinetic-Pharmacodynamic Analysis to Compare, the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects
    Choi, Hyang-Ki
    Jung, Jin Ah
    Fujita, Tomoe
    Amano, Hideki
    Ghim, Jong-Lyul
    Lee, Dong-Hwan
    Tabata, Kenichi
    Song, Il-Dae
    Maeda, Mika
    Kumagai, Yuji
    Mendzelevski, Boaz
    Shin, Jae-Gook
    CLINICAL THERAPEUTICS, 2016, 38 (12) : 2610 - 2621
  • [23] Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling
    Ohk, Boram
    Seong, Sookjin
    Lee, Joomi
    Gwon, Miri
    Kang, Wooyoul
    Lee, Haewon
    Yoon, Youngran
    Yoo, Heedoo
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2022, 43 (01) : 23 - 32
  • [24] Population pharmacokinetic modeling and simulation of choline in healthy Korean subjects after oral administration of choline alfoscerate
    Im, Ae-Gyeoing
    Choi, Go-Wun
    Kang, Dong Wook
    Cho, Seok-jin
    Kim, Jaehee
    Kim, Kyu Yeon
    Cho, Hea-Young
    JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2022, 52 (03) : 331 - 339
  • [25] Population pharmacokinetic modeling and simulation of choline in healthy Korean subjects after oral administration of choline alfoscerate
    Ae-Gyeoing Im
    Go-Wun Choi
    Dong Wook Kang
    Seok-jin Cho
    Jaehee Kim
    Kyu Yeon Kim
    Hea-Young Cho
    Journal of Pharmaceutical Investigation, 2022, 52 : 331 - 339
  • [26] Population Pharmacokinetic Analysis of Istradefylline in Healthy Subjects and in Patients With Parkinson's Disease
    Knebel, William
    Rao, Niranjan
    Uchimura, Tatsuo
    Mori, Akihisa
    Fisher, Jeannine
    Gastonguay, Marc R.
    Chaikin, Philip
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (01): : 40 - 52
  • [27] Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects
    Gonzalez-Sales, Mario
    Barriere, Olivier
    Tremblay, Pierre Olivier
    Nekka, Fahima
    Mamputu, Jean-Claude
    Boudreault, Sylvie
    Tanguay, Mario
    CLINICAL PHARMACOKINETICS, 2015, 54 (03) : 285 - 294
  • [28] Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects
    Mario González-Sales
    Olivier Barrière
    Pierre Olivier Tremblay
    Fahima Nekka
    Jean-Claude Mamputu
    Sylvie Boudreault
    Mario Tanguay
    Clinical Pharmacokinetics, 2015, 54 : 285 - 294
  • [29] Population Pharmacokinetic Analysis of Hydrocodone Following A Single Dose Administration In Healthy Subjects
    Cheruvu, Narayan P.
    Tata, Prasad
    Devarakonda, Krishna R.
    Ward, Julie
    Pierro, Joseph
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1360 - 1360
  • [30] Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy and Hospitalized Subjects with Influenza
    Zuo, Peiying
    Collins, Jon
    Shortino, Denise
    Watson, Helen
    Roberts, Grace
    Peppercorn, Amanda
    Hossain, Mohammad
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S112 - S112